PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-1.10
Negative D/E while Healthcare median is 0.00. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
-5.38
Net cash position versus Healthcare median net debt of 1.38. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-2.74
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.82
Current ratio near Healthcare median of 1.75. David Dodd would examine if industry-standard liquidity is appropriate given business model.
No Data
No Data available this quarter, please select a different quarter.